Curis Q1 net loss $11.9M ($2.05/sh); cash $40.7M; topline AML data May 14

CURIS INC

2024-Q1 EPS reported -$2.05 revenue$2,086,000

Net loss $11.9M vs $11.6M Q1 2023; revenue $2.1M (Erivedge royalties) vs $2.3M.
Cash, equivalents and investments $40.7M as of March 31, 2024; expected to fund operations into 2025.
Topline clinical data from TakeAim Leukemia study (emavusertib monotherapy in R/R AML) to be released May 14, 2024.
Abstracts accepted for ASCO (May 31-Jun 4) and EHA (Jun 13-16); posters on FLT3m and mSF cohorts.
Updated data for R/R PCNSL and frontline AML triplet combo expected late 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CURIS INC reported first quarter ended March 31, 2024 results: revenue $2.1 million, net income net loss of $11.9 million or $2.05 per share on both a basic and diluted basis.

Period: first quarter ended March 31, 2024
Revenue: $2.1 million
Net income: net loss of $11.9 million or $2.05 per share on both a basic and diluted basis
Result: reported results

Exact text from the filing

For the first quarter of 2024, Curis reported a net loss of $11.9 million or $2.05 per share on both a basic and diluted basis as compared to $11.6 million or $2.39 per share on both a basic and diluted basis, for the same period in 2023. Revenues for the first quarter of 2024 were $2.1 million as compared to $2.3 million for the same period in 2023.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

CURIS INC filing history →

Source: SEC EDGAR

accession 0001108205-24-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.